Malar J
185 results
Sequence variation does not confound the measurement of plasma PfHRP2 concentration in African children presenting with severe malaria.Ramutton, T.
Hendriksen, I. C.
Mwanga-Amumpaire, J.
Mtove, G.
Olaosebikan, R.
Tshefu, A. K.
Onyamboko, M. A.
Karema, C.
Maitland, K.
Gomes, E.
Gesase, S.
Reyburn, H.
Silamut, K.
Chotivanich, K.
Promnares, K.
Fanello, C. I.
von Seidlein, L.
Day, N. P.
White, N. J.
Dondorp, A. M.
Imwong, M.
Woodrow, C. J.
Malar J, (2012). 11:276
Human movement data for malaria control and elimination strategic planning.Pindolia, D. K.
Garcia, A. J.
Wesolowski, A.
Smith, D. L.
Buckee, C. O.
Noor, A. M.
Snow, R. W.
Tatem, A. J.
Malar J, (2012). 11:205
Local perceptions of intermittent screening and treatment for malaria in school children on the south coast of Kenya.Okello, G.
Ndegwa, S. N.
Halliday, K. E.
Hanson, K.
Brooker, S. J.
Jones, C.
Malar J, (2012). 11:185
Inaugural meeting of the malaria policy advisory committee to the WHO: conclusions and recommendations.W. H. O. Malaria Policy Advisory Committee
Secretariat,
Malar J, (2012). 11:137
The magnitude and trend of artemether-lumefantrine stock-outs at public health facilities in Kenya.Sudoi, R. K.
Githinji, S.
Nyandigisi, A.
Muturi, A.
Snow, R. W.
Zurovac, D.
Malar J, (2012). 11:37
Impact of insecticide-treated bed nets on malaria transmission indices on the south coast of Kenya.Mutuku, F. M.
King, C. H.
Mungai, P.
Mbogo, C.
Mwangangi, J.
Muchiri, E. M.
Walker, E. D.
Kitron, U.
Malar J, (2011). 10:356
Monitoring fever treatment behaviour and equitable access to effective medicines in the context of initiatives to improve ACT access: baseline results and implications for programming in six African countries.Littrell, M.
Gatakaa, H.
Evance, I.
Poyer, S.
Njogu, J.
Solomon, T.
Munroe, E.
Chapman, S.
Goodman, C.
Hanson, K.
Zinsou, C.
Akulayi, L.
Raharinjatovo, J.
Arogundade, E.
Buyungo, P.
Mpasela, F.
Adjibabi, C. B.
Agbango, J. A.
Ramarosandratana, B. F.
Coker, B.
Rubahika, D.
Hamainza, B.
Shewchuk, T.
Chavasse, D.
O'Connell, K. A.
Malar J, (2011). 10:327
Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries.O'Connell, K. A.
Gatakaa, H.
Poyer, S.
Njogu, J.
Evance, I.
Munroe, E.
Solomon, T.
Goodman, C.
Hanson, K.
Zinsou, C.
Akulayi, L.
Raharinjatovo, J.
Arogundade, E.
Buyungo, P.
Mpasela, F.
Adjibabi, C. B.
Agbango, J. A.
Ramarosandratana, B. F.
Coker, B.
Rubahika, D.
Hamainza, B.
Chapman, S.
Shewchuk, T.
Chavasse, D.
Malar J, (2011). 10:326
The ACTwatch project: methods to describe anti-malarial markets in seven countries.Shewchuk, T.
O'Connell, K. A.
Goodman, C.
Hanson, K.
Chapman, S.
Chavasse, D.
Malar J, (2011). 10:325
Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya.Lawford, H.
Zurovac, D.
O'Reilly, L.
Hoibak, S.
Cowley, A.
Munga, S.
Vulule, J.
Juma, E.
Snow, R. W.
Allan, R.
Malar J, (2011). 10:281
Cost analysis of school-based intermittent screening and treatment of malaria in Kenya.Drake, T. L.
Okello, G.
Njagi, K.
Halliday, K. E.
Jukes, MCh
Mangham, L.
Brooker, S.
Malar J, (2011). 10:273
Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine.Swysen, C.
Vekemans, J.
Bruls, M.
Oyakhirome, S.
Drakeley, C.
Kremsner, P.
Greenwood, B.
Ofori-Anyinam, O.
Okech, B.
Villafana, T.
Carter, T.
Savarese, B.
Duse, A.
Reijman, A.
Ingram, C.
Frean, J.
Ogutu, B.
Clinical Trials Partnership, Committee
Malar J, (2011). 10:223
Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.Vekemans, J.
Marsh, K.
Greenwood, B.
Leach, A.
Kabore, W.
Soulanoudjingar, S.
Asante, K. P.
Ansong, D.
Evans, J.
Sacarlal, J.
Bejon, P.
Kamthunzi, P.
Salim, N.
Njuguna, P.
Hamel, M. J.
Otieno, W.
Gesase, S.
Schellenberg, D.
Clinical Trials Partnership, Committee
Malar J, (2011). 10:221
Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children.Lievens, M.
Aponte, J. J.
Williamson, J.
Mmbando, B.
Mohamed, A.
Bejon, P.
Leach, A.
Malar J, (2011). 10:222
Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.Leach, A.
Vekemans, J.
Lievens, M.
Ofori-Anyinam, O.
Cahill, C.
Owusu-Agyei, S.
Abdulla, S.
Macete, E.
Njuguna, P.
Savarese, B.
Loucq, C.
Ballou, W. R.
Clinical Trials Partnership, Committee
Malar J, (2011). 10:224
Global proteomic analysis of plasma from mice infected with Plasmodium berghei ANKA using two dimensional gel electrophoresis and matrix assisted laser desorption ionization-time of flight mass spectrometry.Gitau, E. N.
Kokwaro, G. O.
Newton, C. R.
Ward, S. A.
Malar J, (2011). 10:205
Treatment of African children with severe malaria - towards evidence-informed clinical practice using GRADE.Musila, N.
Opiyo, N.
English, M.
Malar J, (2011). 10:201
The clinical burden of malaria in Nairobi: a historical review and contemporary audit.Mudhune, S. A.
Okiro, E. A.
Noor, A. M.
Zurovac, D.
Juma, E.
Ochola, S. A.
Snow, R. W.
Malar J, (2011). 10:138
Self-reported fever, treatment actions and malaria infection prevalence in the northern states of Sudan.Elmardi, K. A.
Noor, A. M.
Githinji, S.
Abdelgadir, T. M.
Malik, E. M.
Snow, R. W.
Malar J, (2011). 10:128
A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers.Chilengi, R.
Juma, R.
Abdallah, A. M.
Bashraheil, M.
Lodenyo, H.
Nyakundi, P.
Anabwani, E.
Salim, A.
Mwambingu, G.
Wenwa, E.
Jemutai, J.
Kipkeu, C.
Oyoo, G. O.
Muchohi, S. N.
Kokwaro, G.
Niehues, T.
Lang, T.
Nzila, A.
Malar J, (2011). 10:63